Page 115 - Read Online

Page 30 of 34 West et al. Rare Dis Orphan Drugs J 2024;3:22 https://dx.doi.org/10.20517/rdodj.2023.61

patients with Fabry disease. J Am Soc Nephrol 2007;18:1547-57. DOI
73. Najafian B, Svarstad E, Bostad L, et al. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young
patients with Fabry disease. Kidney Int 2011;79:663-70. DOI PubMed PMC
74. Najafian B, Tøndel C, Svarstad E, Gubler MC, Oliveira JP, Mauer M. Accumulation of globotriaosylceramide in podocytes in Fabry
nephropathy is associated with progressive podocyte loss. J Am Soc Nephrol 2020;31:865-75. DOI PubMed PMC
75. Najafian B, Silvestroni A, Sokolovskiy A, et al. A novel unbiased method reveals progressive podocyte globotriaosylceramide
accumulation and loss with age in females with Fabry disease. Kidney Int 2022;102:173-82. DOI PubMed PMC
76. Braun F, Abed A, Sellung D, et al. Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy. J Clin Invest
2023:133. DOI
77. Schiffmann R. Investigating Fabry disease - some lessons learned. Rare Dis Orphan Drugs J 2024;3:4. DOI
78. Jennette, JC, D’Agati, VD. Heptinstall’s pathology of the kidney, 7th ed. Philadelphia: Lippincott Williams and Wilkins; 2014. pp
1232-4. DOI
79. Colvin RB. Fabry disease. In: Colvin RB, Chang A, editors. Diagnostic pathology: kidney diseases, 3rd ed. Philadelphia: Elsevier;
2019. pp. 400-1.
80. Gubler MC, Lenoir G, Grünfeld JP, Ulmann A, Droz D, Habib R. Early renal changes in hemizygous and heterozygous patients with
Fabry’s disease. Kidney Int 1978;13:223-35. DOI PubMed
81. Svarstad E, Leh S, Skrunes R, Kampevold Larsen K, Eikrem Ø, Tøndel C. Bedside stereomicroscopy of Fabry kidney biopsies: an
easily available method for diagnosis and assessment of sphingolipid deposits. Nephron 2018;138:13-21. DOI PubMed
82. Colpart P, Félix S. Fabry nephropathy. Arch Pathol Lab Med 2017;141:1127-31. DOI PubMed
83. Elleder M, Poupetova H, Kozich V. [Fetal pathology in Fabry's disease and mucopolysaccharidosis type I]. Cesk Patol 1998;34:7-12.
PubMed
84. Reasor MJ, Hastings KL, Ulrich RG. Drug-induced phospholipidosis: issues and future directions. Expert Opin Drug Saf 2006;5:567-
83. DOI PubMed
85. Grafft CA, Fervenza FC, Semret MH, Orloff S, Sethi S. Renal involvement in neimann-pick disease. NDT Plus 2009;2:448-51. DOI
PubMed PMC
86. Banks DE, Milutinovic J, Desnick RJ, Grabowski GA, Lapp NL, Boehlecke BA. Silicon nephropathy mimicking Fabry’s disease. Am
J Nephrol 1983;3:279-84. DOI PubMed
87. Lei L, Oh G, Sutherland S, et al. Myelin bodies in LMX1B-associated nephropathy: potential for misdiagnosis. Pediatr Nephrol
2020;35:1647-57. DOI
88. Hirashio S, Ueno T, Naito T, Masaki T. Characteristic kidney pathology, gene abnormality and treatments in LCAT deficiency. Clin
Exp Nephrol 2014;18:189-93. DOI PubMed
89. Ni HF, Yang Y, Li CQ, Zhou TZ, Liu BC, Wang B. Myeloid bodies caused by COQ2 mutation: a case of concurrent COQ2
nephropathy and IgA nephropathy. Clin Kidney J 2021;14:1697-700. DOI PubMed PMC
90. Su H, Ye C, Wen Q, Zhu HY, Yi LX, Zhang C. Case report: lipid inclusion in glomerular endothelial and mesangial cells in a patient
after contrast medium injection. BMC Nephrol 2018;19:53. DOI PubMed PMC
91. Hull MT, Eble JN. Myelinoid lamellated cytoplasmic inclusions in human renal adenocarcinomas: an ultrastructural study.
Ultrastruct Pathol 1988;12:41-8. DOI PubMed
92. Kadosawa K, Morikawa T, Konishi Y. Zebra bodies without Fabry disease or hydroxychloroquine. Clin Exp Nephrol 2021;25:94-6.
DOI PubMed
93. Tøndel C, Kanai T, Larsen KK, et al. Foot process effacement is an early marker of nephropathy in young classic Fabry patients
without albuminuria. Nephron 2015;129:16-21. DOI
94. Tøndel C, Bostad L, Hirth A, Svarstad E. Renal biopsy findings in children and adolescents with Fabry disease and minimal
albuminuria. Am J Kidney Dis 2008;51:767-76. DOI PubMed
95. Valbuena C, Leitão D, Carneiro F, Oliveira JP. Immunohistochemical diagnosis of Fabry nephropathy and localisation of
globotriaosylceramide deposits in paraffin-embedded kidney tissue sections. Virchows Arch 2012;460:211-21. DOI PubMed
96. Mauer M, Glynn E, Svarstad E, et al. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.
PLoS One 2014;9:e112188. DOI PubMed PMC
97. Fogo AB, Bostad L, Svarstad E, et al. Scoring system for renal pathology in Fabry disease: report of the international study group of
fabry nephropathy (ISGFN). Nephrol Dial Transplant 2010;25:2168-77. DOI PubMed PMC
98. Müller-Höcker J, Schmid H, Weiss M, Dendorfer U, Braun GS. Chloroquine-induced phospholipidosis of the kidney mimicking
Fabry’s disease: case report and review of the literature. Hum Pathol 2003;34:285-9. DOI PubMed
99. Renwick N, Nasr SH, Chung WK, et al. Foamy podocytes. Am J Kidney Dis 2003;41:891-6. DOI
100. Chen TK, Knicely DH, Grams ME. Chronic kidney disease diagnosis and management: a review. JAMA 2019;322:1294-304. DOI
PubMed PMC
101. Francini-Pesenti F, Ravarotto V, Bertoldi G, Spinella P, Calò LA. Could nutritional therapy take us further in our approaches to Fabry
disease? Nutrition 2020;72:110664. DOI PubMed
102. Mroczek M, Maniscalco I, Sendel M, Baron R, Seifritz E, Nowak A. Neuropsychiatric symptoms and their association with sex, age,
and enzyme replacement therapy in Fabry disease: a systematic review. Front Psychiatry 2022;13:829128. DOI PubMed PMC
103. Tahir H, Jackson LL, Warnock DG. Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients